MCID: CHL149
MIFTS: 42

Childhood Acute Myeloid Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Childhood Acute Myeloid Leukemia

MalaCards integrated aliases for Childhood Acute Myeloid Leukemia:

Name: Childhood Acute Myeloid Leukemia 12 17
Pediatric Acute Myeloid Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0070323
NCIt 51 C9160

Summaries for Childhood Acute Myeloid Leukemia

Disease Ontology : 12 A childhood leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

MalaCards based summary : Childhood Acute Myeloid Leukemia, also known as pediatric acute myeloid leukemia, is related to leukemia and myeloid sarcoma. An important gene associated with Childhood Acute Myeloid Leukemia is NSD1 (Nuclear Receptor Binding SET Domain Protein 1), and among its related pathways/superpathways is Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are growth/size/body region and embryo

Related Diseases for Childhood Acute Myeloid Leukemia

Diseases related to Childhood Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
# Related Disease Score Top Affiliating Genes
1 leukemia 31.2 FLT3 NPM1 WT1
2 myeloid sarcoma 29.8 FLT3 NPM1
3 myeloid leukemia 29.6 DNMT3A FLT3 NPM1 NUP98 TET2 WT1
4 wilms tumor 1 29.4 FLT3 NPM1 WT1
5 leukemia, acute myeloid 29.3 DNMT3A FLT3 NPM1 NSD1 NUP98 TET2
6 myelodysplastic syndrome 28.1 DNMT3A FLT3 NPM1 NUP98 TET2 WT1
7 central nervous system disease 10.2
8 nervous system disease 10.2
9 lymphoma 10.1
10 acute myeloblastic leukemia without maturation 10.1 FLT3 NPM1
11 wilms tumor 5 10.1
12 leukemia, acute lymphoblastic 10.1
13 wilms tumor 6 10.1
14 hematopoietic stem cell transplantation 10.1
15 lymphocytic leukemia 10.1
16 sarcoma 10.1
17 hypereosinophilic syndrome 10.1
18 chromosomal triplication 10.0
19 acute myeloblastic leukemia with maturation 10.0 FLT3 NPM1
20 chronic eosinophilic leukemia 10.0 FLT3 WT1
21 aleukemic leukemia cutis 10.0 FLT3 NPM1
22 core binding factor acute myeloid leukemia 10.0 FLT3 WT1
23 down syndrome 9.9
24 disorganization, mouse, homolog of 9.9
25 fanconi anemia, complementation group a 9.9
26 fanconi anemia, complementation group d1 9.9
27 acute lymphocytic leukemia 9.9
28 megakaryocytic leukemia 9.9
29 severe combined immunodeficiency 9.9
30 sinusitis 9.9
31 systemic mastocytosis 9.9
32 osteomyelitis 9.9
33 mastocytosis 9.9
34 combined t cell and b cell immunodeficiency 9.9
35 childhood leukemia 9.9
36 granulocytopenia 9.9
37 xp22.3 microdeletion syndrome 9.9
38 neutropenia 9.9
39 spindle cell sarcoma 9.9
40 acute leukemia 9.9 FLT3 WT1
41 subacute myeloid leukemia 9.9 FLT3 TET2
42 leukemia, chronic myeloid 9.8 FLT3 NUP98 WT1
43 precursor t-cell acute lymphoblastic leukemia 9.8 FLT3 NUP98
44 cytogenetically normal acute myeloid leukemia 9.8 FLT3 NPM1 WT1
45 blastic plasmacytoid dendritic cell 9.7 NPM1 TET2
46 chronic leukemia 9.7 TET2 WT1
47 acute promyelocytic leukemia 9.5 FLT3 NPM1 WT1
48 chronic myelomonocytic leukemia 9.5 DNMT3A FLT3 TET2
49 juvenile myelomonocytic leukemia 9.5 DNMT3A FLT3 TET2
50 hematologic cancer 9.1 FLT3 NPM1 NUP98 TET2 WT1

Graphical network of the top 20 diseases related to Childhood Acute Myeloid Leukemia:



Diseases related to Childhood Acute Myeloid Leukemia

Symptoms & Phenotypes for Childhood Acute Myeloid Leukemia

MGI Mouse Phenotypes related to Childhood Acute Myeloid Leukemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.85 DNMT3A FLT3 NPM1 NUP98 TET2 WT1
2 embryo MP:0005380 9.8 DNMT3A NPM1 NSD1 NUP98 WT1
3 hematopoietic system MP:0005397 9.8 DNMT3A FLT3 NPM1 NUP98 TET2 WT1
4 immune system MP:0005387 9.73 DNMT3A FLT3 NPM1 NUP98 TET2 WT1
5 mortality/aging MP:0010768 9.7 DNMT3A FLT3 NPM1 NSD1 NUP98 TET2
6 neoplasm MP:0002006 9.26 FLT3 NPM1 TET2 WT1
7 no phenotypic analysis MP:0003012 8.92 FLT3 NSD1 TET2 WT1

Drugs & Therapeutics for Childhood Acute Myeloid Leukemia

Drugs for Childhood Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
4
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
5
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
6
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
7
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
8
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
17 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Micronutrients Phase 4,Phase 2
19 Nutrients Phase 4,Phase 2
20 Trace Elements Phase 4,Phase 2
21 Ergocalciferols Phase 4
22 Calciferol Phase 4
23 Vitamins Phase 4
24 Hydroxycholecalciferols Phase 4
25 Vitamin D2 Phase 4
26
Aldesleukin Approved Phase 3,Phase 2,Phase 1 110942-02-4, 85898-30-2
27
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 2713 9552079
28
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
29
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
30
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
31
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
32
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
33
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
34
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
35
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
36
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
37
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
38
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
39
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
40
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 302-25-0
41
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2921-57-5
42
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 460612 4053
43
Daunorubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
44
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
45
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
46
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-23-7 5754
47
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-03-3
48
Arsenic trioxide Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 1327-53-3 518740
49
Mercaptopurine Approved Phase 3,Phase 2,Not Applicable 50-44-2 667490
50
Caspofungin Approved Phase 3,Not Applicable 162808-62-0, 179463-17-3 2826718 468682

Interventional clinical trials:

(show top 50) (show all 369)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
3 Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2 Unknown status NCT00149162 Phase 3 proleukin
4 Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant Unknown status NCT01817075 Phase 3 Chlorhexidine Gluconate
5 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
6 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Completed NCT00866918 Phase 3 arsenic trioxide;mitoxantrone hydrochloride;idarubicin;tretinoin;cytarabine;mercaptopurine tablet;methotrexate
7 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
8 Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00003934 Phase 3 tretinoin;daunorubicin hydrochloride;cytarabine;mercaptopurine;methotrexate;arsenic trioxide
9 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
10 Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
11 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Completed NCT01371656 Phase 3 levofloxacin
12 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
13 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
14 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
15 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
16 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
17 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
18 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
19 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
20 Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
21 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
22 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
23 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
24 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
25 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
26 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
27 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
28 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
29 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
30 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
31 Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Completed NCT00002456 Phase 3 cyclosporine;methotrexate
32 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
33 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
34 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
35 Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years Recruiting NCT01828489 Phase 3 Randomisation course 1 mitoxantrone versus DaunoXome;Randomisation course 2 ADxE versus FLADx
36 Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Recruiting NCT00630565 Phase 2, Phase 3 busulfan;cyclophosphamide;dexamethasone;etoposide
37 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
38 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3
39 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
40 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
41 Bone Marrow Transplantation in Treating Patients With Leukemia Withdrawn NCT00006451 Phase 3 anti-thymocyte globulin;cyclophosphamide;cyclosporine;methotrexate;methylprednisolone
42 Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML Unknown status NCT01274195 Phase 2 Busulfan
43 Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML Unknown status NCT00887042 Phase 1, Phase 2 Fludarabine, Busulfan, Thymoglobulin
44 Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00553202 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;methylprednisolone;tacrolimus
45 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
46 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
47 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
48 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
49 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
50 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2

Search NIH Clinical Center for Childhood Acute Myeloid Leukemia

Genetic Tests for Childhood Acute Myeloid Leukemia

Anatomical Context for Childhood Acute Myeloid Leukemia

MalaCards organs/tissues related to Childhood Acute Myeloid Leukemia:

42
Myeloid, Bone, Bone Marrow, T Cells, Kidney, Testes, Colon

Publications for Childhood Acute Myeloid Leukemia

Articles related to Childhood Acute Myeloid Leukemia:

(show top 50) (show all 455)
# Title Authors Year
1
Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study. ( 30550508 )
2019
2
Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium. ( 30776582 )
2019
3
CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/β-catenin signaling pathway. ( 30862962 )
2019
4
Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values. ( 30900388 )
2019
5
Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia. ( 30954792 )
2019
6
Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01. ( 30623572 )
2019
7
Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia. ( 31044544 )
2019
8
Prognostic impact of mitochondrial DNA D-loop variations in pediatric acute myeloid leukemia. ( 30863493 )
2019
9
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. ( 30894213 )
2019
10
Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment. ( 30732497 )
2019
11
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. ( 30760869 )
2019
12
Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. ( 30705421 )
2019
13
Pediatric acute myeloid leukemia with t(7;21)(p22;q22). ( 30706625 )
2019
14
Lnc-SOX6-1 upregulation correlates with poor risk stratification and worse treatment outcomes, and promotes cell proliferation while inhibits apoptosis in pediatric acute myeloid leukemia. ( 30624855 )
2019
15
Comparable on-therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia. ( 30585685 )
2019
16
Apoptosis: A biomarker of high-risk phenotype in pediatric acute myeloid leukemia? ( 30383325 )
2019
17
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. ( 30089916 )
2019
18
High incidence of acute kidney injury during chemotherapy for childhood acute myeloid leukemia. ( 29286559 )
2018
19
Genomics in childhood acute myeloid leukemia comes of age. ( 29315296 )
2018
20
Abandonment and Outcome of Childhood Acute Myeloid Leukemia in A Tertiary Level Hospital. ( 29459598 )
2018
21
The chromatin-remodeling factor CHD4 is required for maintenance of childhood acute myeloid leukemia. ( 29599201 )
2018
22
Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. ( 29608923 )
2018
23
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia. ( 29615816 )
2018
24
Comparison of survival outcome between donor types or stem cell sources for childhood acute myeloid leukemia after allogenic hematopoietic stem cell transplantation: A multicenter retrospective study of Study Alliance of Yeungnam Pediatric Hematology-oncology. ( 29923253 )
2018
25
A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia. ( 30338031 )
2018
26
Identifying Prognostic Factors That Influence Outcome of Childhood Acute Myeloid Leukemia in First Relapse in Saudi Arabia: Results of the Multicenter SAPHOS Study. ( 30340992 )
2018
27
Treatment of Childhood Acute Myeloid Leukemia in Bulgaria. ( 30355812 )
2018
28
Leukemia Cutis in Childhood Acute Myeloid Leukemia: Epidemiological, Clinical, Biological, and Prognostic Characteristics of Patients Included in the ELAM02 Study. ( 30887005 )
2018
29
Prognostic Value of EVI1 Expression in Pediatric Acute Myeloid Leukemia: A Systematic Review. ( 30636951 )
2018
30
Genetics-based Risk Stratification of Pediatric Acute Myeloid Leukemia in India. ( 30587658 )
2018
31
Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series. ( 30543582 )
2018
32
Targeting Hedgehog pathway in pediatric acute myeloid leukemia: challenges and opportunities. ( 30556755 )
2018
33
MiR-10b regulates the proliferation and apoptosis of pediatric acute myeloid leukemia through targeting HOXD10. ( 30468483 )
2018
34
Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. ( 30088438 )
2018
35
Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. ( 30101002 )
2018
36
A case of pediatric acute myeloid leukemia with t(11;16)(q23;q24) leading to a novel KMT2A-USP10 fusion gene. ( 30107050 )
2018
37
Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia. ( 29893458 )
2018
38
Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. ( 29928480 )
2018
39
Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. ( 29933069 )
2018
40
Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. ( 29950694 )
2018
41
Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia. ( 29781563 )
2018
42
Pattern of mitochondrial D-loop variations and their relation with mitochondrial encoded genes in pediatric acute myeloid leukemia. ( 29883862 )
2018
43
Current treatment for pediatric acute myeloid leukemia. ( 29662852 )
2018
44
Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. ( 29669821 )
2018
45
Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia. ( 29689705 )
2018
46
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. ( 29550834 )
2018
47
Impact of the D-index deduced from duration and intensity of neutropenia following chemotherapy on the risk of invasive fungal infection in pediatric acute myeloid leukemia. ( 29564800 )
2018
48
Erratum: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. ( 29634680 )
2018
49
RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. ( 29540347 )
2018
50
Clinical challenges in de novo pediatric acute myeloid leukemia. ( 29338495 )
2018

Variations for Childhood Acute Myeloid Leukemia

Expression for Childhood Acute Myeloid Leukemia

Search GEO for disease gene expression data for Childhood Acute Myeloid Leukemia.

Pathways for Childhood Acute Myeloid Leukemia

Pathways related to Childhood Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.97 DNMT3A FLT3

GO Terms for Childhood Acute Myeloid Leukemia

Cellular components related to Childhood Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.17 DNMT3A FLT3 NPM1 NSD1 NUP98 TET2

Biological processes related to Childhood Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.5 NPM1 NSD1 WT1
2 viral process GO:0016032 9.33 FLT3 NPM1 NUP98
3 negative regulation of apoptotic process GO:0043066 9.26 NPM1 WT1
4 chromatin organization GO:0006325 9.13 DNMT3A NSD1 TET2
5 nucleocytoplasmic transport GO:0006913 8.62 NPM1 NUP98

Molecular functions related to Childhood Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 8.8 DNMT3A NPM1 NSD1

Sources for Childhood Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....